Related Experiment Video
Updated: Aug 27, 2025
Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
De novo sphingolipid biosynthesis necessitates detoxification in cancer cells
Meghan E Spears1, Namgyu Lee1, Sunyoung Hwang1
1Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01604, USA.
Abstract:
Sphingolipids play important signaling and structural roles in cells. Here, we find that during de novo sphingolipid biosynthesis, a toxic metabolite is formed with critical implications for cancer cell survival. The enzyme catalyzing the first step in this pathway, serine palmitoyltransferase complex (SPT), is upregulated in breast and other cancers. SPT is dispensable for cancer cell proliferation, as sphingolipids can be salvaged from the environment. However, SPT activity introduces a liability as its product, 3-ketodihydrosphingosine (3KDS), is toxic and requires clearance via the downstream enzyme 3-ketodihydrosphingosine reductase (KDSR). In cancer cells, but not normal cells, targeting KDSR induces toxic 3KDS accumulation leading to endoplasmic reticulum (ER) dysfunction and loss of proteostasis. Furthermore, the antitumor effect of KDSR disruption can be enhanced by increasing metabolic input (via high-fat diet) to allow greater 3KDS production. Thus, de novo sphingolipid biosynthesis entails a detoxification requirement in cancer cells that can be therapeutically exploited.
Insights
Cancer cells produce a toxic sphingolipid metabolite requiring detoxification. Targeting the KDSR enzyme disrupts this process, causing cell death and offering a potential cancer therapy.
Area of Science:
- Cellular metabolism
- Cancer biology
- Biochemistry
Background:
- Sphingolipids are crucial for cellular structure and signaling.
- De novo sphingolipid biosynthesis can generate toxic metabolites.
- The enzyme serine palmitoyltransferase complex (SPT) is upregulated in various cancers.
Purpose of the Study:
- Investigate the role of de novo sphingolipid biosynthesis in cancer cell survival.
- Identify vulnerabilities in the sphingolipid biosynthesis pathway for therapeutic targeting.
- Explore the implications of toxic metabolite accumulation in cancer cells.
Main Methods:
- Enzyme activity assays
- Cell culture experiments
- Analysis of endoplasmic reticulum (ER) stress and proteostasis
- Metabolic manipulation studies (e.g., high-fat diet)
Main Results:
- The product of SPT, 3-ketodihydrosphingosine (3KDS), is toxic and requires clearance by KDSR.
- Targeting KDSR in cancer cells leads to toxic 3KDS accumulation.
- This accumulation causes ER dysfunction and loss of proteostasis, selectively harming cancer cells.
- Antitumor effects are enhanced by increased metabolic input, promoting 3KDS production.
Conclusions:
- De novo sphingolipid biosynthesis creates a detoxification requirement in cancer cells.
- Inhibition of KDSR represents a potential therapeutic strategy against cancer.
- Metabolic interventions can potentiate the efficacy of targeting sphingolipid metabolism in cancer treatment.
More Related Videos
13:36Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
Published on: October 20, 2023
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:35Cancer Cell Migration through Invadopodia
01:20Sulfur Assimilation